IL-2

Natural Killer (NK) Cells in Combination With Interleukin-2 (IL-2) and Transforming Growth Factor Beta (TGFbeta) Receptor I Inhibitor Vactosertib in Cancer

PICSTAT Pilot Study for CD8 PET/CT-Guided Lifileucel Treatment in Advanced Melanoma

Adapt NK for High Risk Myeloid Diseases as Bridge to Allo HSCT

Pilot Study of Memory-like Natural Killer (ML NK) Cells After TCRαβ T Cell Depleted Haploidentical Transplant in AML

TREg Activation in the Treatment of the PELADE (Alopecia Areata)

FT819 in Subjects With B-cell Malignancies

Natural Killer-cell Therapy for Acute Myeloid Leukemia

Dose-escalation and Dose-expansion Study of Safety of Azer-cel (PBCAR0191) in Participants With Relapsed/Refractory (r/r) Non-Hodgkin Lymphoma (NHL) and r/r B-cell Acute Lymphoblastic Leukemia (B-ALL)

UCDCC#272: IL-2, Radiotherapy, and Pembrolizumab in Patients Refractory to Checkpoint Blockade

HPV16 E6 TCR T Cells for Cervical Carcinoma

A Study of CNTY-101 in Participants With Refractory B Cell-mediated Autoimmune Diseases

Study of Autologous Peripheral Blood Lymphocytes in the Treatment of Patients With CLL or SLL

A Study of CNTY-101 in Participants With CD19-Positive B-Cell Malignancies

MIROCALS: Modifying Immune Response and OutComes in ALS

NY-ESO-1 TCR-T Cells for NY-ESO-1 Positive Subjects With Advanced Solid Tumors

A Clinical Study of the Safety and Activity of the Investigational Cell Therapy NEO-PTC-01 in Patients With Advanced Melanoma

Phase I Clinical Study of Tumor-associated Lymph Node T Cell Therapy for Advanced Solid Tumors

Adoptive Transfer of iNKT Cells for Treating Patients With Relapsed/Advanced HCC

Vaccination with Autologous Dendritic Cells Loaded with Autologous Tumour Homogenate After Curative Resection for Stage IV Colorectal Cancer.

Cytokine-induced Memory-like NK Cells in Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)